Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Men’s perspectives of prostate cancer screening: A systematic review of qualitative studies

  • Laura J. James ,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Writing – original draft, Writing – review & editing

    Affiliations Sydney School of Public Health, The University of Sydney, Sydney, Australia, Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia

  • Germaine Wong,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Writing – review & editing

    Affiliations Sydney School of Public Health, The University of Sydney, Sydney, Australia, Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia, Centre for Transplant and Renal Research, Westmead Hospital, Westmead, Australia

  • Jonathan C. Craig,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Writing – review & editing

    Affiliations Sydney School of Public Health, The University of Sydney, Sydney, Australia, Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia

  • Camilla S. Hanson,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing – review & editing

    Affiliations Sydney School of Public Health, The University of Sydney, Sydney, Australia, Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia

  • Angela Ju,

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Software, Writing – review & editing

    Affiliations Sydney School of Public Health, The University of Sydney, Sydney, Australia, Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia

  • Kirsten Howard,

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Writing – review & editing

    Affiliation Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia

  • Tim Usherwood,

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Writing – review & editing

    Affiliations Department of General Practice, Westmead Clinical School, The University of Sydney, Sydney, Australia, The George Institute for Global Health, Sydney, Australia

  • Howard Lau,

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Writing – review & editing

    Affiliation Department of Urology, Westmead Hospital, Westmead, Australia

  • Allison Tong

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Software, Supervision, Writing – review & editing

    Affiliations Sydney School of Public Health, The University of Sydney, Sydney, Australia, Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Australia

Men’s perspectives of prostate cancer screening: A systematic review of qualitative studies

  • Laura J. James, 
  • Germaine Wong, 
  • Jonathan C. Craig, 
  • Camilla S. Hanson, 
  • Angela Ju, 
  • Kirsten Howard, 
  • Tim Usherwood, 
  • Howard Lau, 
  • Allison Tong



Prostate cancer is the most commonly diagnosed non-skin cancer in men. Screening for prostate cancer is widely accepted; however concerns regarding the harms outweighing the benefits of screening exist. Although patient’s play a pivotal role in the decision making process, men may not be aware of the controversies regarding prostate cancer screening. Therefore we aimed to describe men’s attitudes, beliefs and experiences of prostate cancer screening.


Systematic review and thematic synthesis of qualitative studies on men’s perspectives of prostate cancer screening. Electronic databases and reference lists were searched to October 2016.


Sixty studies involving 3,029 men aged from 18–89 years, who had been screened for prostate cancer by Prostate Specific Antigen (PSA) or Digital Rectal Examination (DRE) and not screened, across eight countries were included. Five themes were identified: Social prompting (trusting professional opinion, motivation from family and friends, proximity and prominence of cancer); gaining decisional confidence (overcoming fears, survival imperative, peace of mind, mental preparation, prioritising wellbeing); preserving masculinity (bodily invasion, losing sexuality, threatening manhood, medical avoidance); avoiding the unknown and uncertainties (taboo of cancer-related death, lacking tangible cause, physiological and symptomatic obscurity, ambiguity of the procedure, confusing controversies); and prohibitive costs.


Men are willing to participate in prostate cancer screening to prevent cancer and gain reassurance about their health, particularly when supported or prompted by their social networks or healthcare providers. However, to do so they needed to mentally overcome fears of losing their masculinity and accept the intrusiveness of screening, the ambiguities about the necessity and the potential for substantial costs. Addressing the concerns and priorities of men may facilitate informed decisions about prostate cancer screening and improve patient satisfaction and outcomes.


Prostate cancer is the most commonly diagnosed non-skin cancer in men and accounts for 48 deaths per 100,000 men per year in the UK.[1] One in seven men in Australia and the UK will develop prostate cancer by age 75 years.[2, 3] The overall age-standardised incidence is 182 per 100,000 men per year in the UK,[4] and 163 and 129 per 100,000 men per year in Australia and US respectively.[5, 6]

Screening for prostate cancer using prostate-specific antigen (PSA) is widely used in the general population, contributing to a threefold increase in the incidence of diagnosed prostate cancer.[7] However, screening remains controversial, in part due to conflicting results from recent large randomised controlled trials. One large-scale trial, conducted in the US, found no difference in prostate cancer mortality between the screened and control group after 13 years,[8] whereas another European trial, with a similar follow up, demonstrated a 21% relative reduction in the risk of prostate cancer-specific death.[9]

More recently, concerns about overdiagnosis have also been raised.[1012] Early detection through screening can lead to overdiagnosis, which consequently may require further unnecessary investigations, including prostatectomy and radiation therapy.[10] It remains uncertain whether screening confers appreciable survival benefits, and treatment of screen detected disease can lead to adverse events including urinary incontinence, erectile dysfunction, bowel problems, and unwarranted anxiety.[10, 13] As a result, current guidelines for PSA testing vary worldwide.

The conflicting trial results, potential harms associated with the screening algorithm, and the inconsistent recommendations regarding PSA testing in clinical practice guidelines,[2, 11, 1416] highlights the critical role of patient preference. Shared informed decision making is widely advocated to ensure men can understand and weigh the benefits and harms of prostate cancer screening.[2, 11, 12, 14, 1618] However, men may not be aware of the potential risks of treating screen-detected prostate cancer.[1921] Although a clinician’s recommendation to screen is associated with higher uptake of prostate cancer screening[2225], embarrassment,[2629] perceived low risk,[28, 30] and fear of cancer [28, 31, 32] explain men’s decisions not to undergo screening. We aimed to describe the beliefs, attitudes and experiences of men on prostate cancer screening. A broader range of insights across populations and healthcare settings will provide a comprehensive understanding of men’s perspectives on prostate cancer screening, and may also enable comparisons across demographic characteristics. This may inform strategies for informed, shared-decision making that explicitly considers their values and preferences.


This study follows the Enhancing Transparency of Reporting the Synthesis of Qualitative research (ENTREQ) framework.[33] ENTREQ covers five main domains for reporting the systematic review of primary qualitative studies: introduction, methods and methodology, literature search and selection, appraisal, and synthesis of findings.

Selection criteria

We included qualitative studies that used interviews or focus groups which elicited perspectives of adult men, of any age, on prostate cancer screening. To obtain a broad range of perspectives on attitudes to screening, studies of men with no previous history of screening or had been screened for prostate cancer using PSA or digital rectal examination (DRE) were included. We excluded studies that only included men diagnosed with prostate cancer, or that included health professionals. Studies published in non-English language were excluded to prevent cultural and linguistic bias in translations. We also excluded studies if they used structured surveys and reported only quantitative data, or were epidemiological studies, editorials or reviews.

Data sources and searches

We searched MEDLINE, Embase, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) from inception to October 2016 (S1 Text), as well as Google Scholar and the reference lists of relevant studies and reviews. Author (LJJ) screened titles and abstracts of search results and excluded those that did not meet the selection criteria. Full texts of the remaining articles were assessed for study eligibility by LJJ.

Quality of reporting assessment

Three authors (LJJ/CSH/AJ) independently evaluated the transparency of reporting of each included study using the Consolidated Criteria for Reporting Qualitative Research (COREQ) framework.[34] The COREQ items addresses the research team, relationship with participants, participant selection, setting, data collection, data analysis and reporting. Discrepancies were discussed and resolved among the reviewers.


We synthesised the results from all included studies using thematic synthesis, as described by Thomas and Harden.[35] All text and quotations included within the “Results” or “Discussion/Conclusion” section from the included studies were imported into HyperRESEARCH (ResearchWare, INC. 2015, version 3.7.1) software for qualitative data management. LJJ read each study, conducted line-by-line coding of the findings, and inductively identified concepts relating to prostate cancer screening perspectives and grouped similar concepts into themes and subthemes. Three authors (LJJ, CSH, AJ) read the papers independently to ensure that the range and depth of data reported in the included studies were included in the analytical framework. Conceptual links among these themes were identified and mapped into a thematic schema.


Literature search

Of the 2,752 articles retrieved, 68 eligible studies involving 3,029 participants were identified (Fig 1). The characteristics of the studies are provided in Table 1 and S1 Table. Forty studies (59%) included men with and without a history of screening. Nine (13%) studies included men who had not been screened, and 4 (6%) studies included men who had been previously screened. Fifteen (22%) studies did not report participant’s history of screening. Both methods for screening, PSA or DRE, were used, however the number of men that used either method was not reported in most studies. The studies were conducted in nine countries, including the United States (49 [72%]; of which 26 (38%) only included African American men), United Kingdom (7 [10%]), Australia (6 [9%]), Barbados, Belgium, Canada, Germany, Nigeria and Uganda (1 study each).

Comprehensiveness of reporting of included studies

The comprehensiveness of reporting was variable, with studies reporting 7 to 23 of the 25 items in the adapted COREQ checklist (Table 2). The participant selection strategy was described in 58 (85%) studies, and data saturation was reported in 28 (41%) studies. The use of software to facilitate data analysis was reported in 41 (60%) studies, and 52 (76%) reported on the use of researcher triangulation. Almost all studies (66 [97%]) provided participant quotations.

Table 2. Comprehensiveness of reporting in included studies.


We identified five themes on men’s perspectives on prostate cancer screening: social prompting, gaining decisional confidence, preserving masculinity, avoiding the unknown and uncertainties, and prohibitive costs. The respective subthemes are described below. Table 3 provides selected participant quotations from the included studies, and indicates the studies that contributed to each theme. A thematic schema to illustrate the conceptual links among themes is provided in Fig 2.

Social prompting.

Trusting professional opinion–Some participants had “confidence in doctors” to initiate and make recommendations about prostate cancer screening.[19, 27, 28, 38, 47, 49, 52, 54, 59, 60, 78, 81, 83, 91, 93] Many felt overwhelmed by the complicated medical information and thus did not feel competent enough to “evaluate the pros and cons or the risks” on their own.[38, 52] Having a strong relationship with their health care provider allowed participants to make this important health decision for them.[78]

Motivation from family and friendsFamily and friends motivated men to be screened for prostate cancer.[40, 41, 47, 5557, 71, 72, 79, 83, 91, 92, 99] Participants appreciated their spouses’ encouragement, their constant “nagging”[79] to pursue screening and “for sticking by”,[47] during the decision making and screening process. Having a family member who had prostate-related problems (e.g. benign prostatic hyperplasia) also prompted them to undergo screening, as they “wouldn’t have started checking”[69] otherwise.[65, 69, 83, 91, 98]

Proximity and prominence of cancerParticipants who had seen the devastating impact of cancer among their family or friends felt acutely aware of cancer, and were prompted to undergo prostate cancer screening.[21, 42, 47, 51, 60, 65, 66, 69, 75, 83, 85, 91, 100] The death of family members due to cancer and “seeing what [they] went through”[51] as well as understanding the potential of cancer “running in the family,”[66] caused participants to become proactive about cancer screening, including for prostate cancer. Some believed their family members had cancer detected “too late”.[75]

Gaining decisional confidence.

Overcoming fearsPreparing to screen for prostate cancer was described by participants as a “psychological game”[19] that required them to overcome the stigma surrounding the screening procedure.[19, 27, 55, 61, 81, 82] Prostate cancer screening was initially perceived as “embarrassing,”[81] “uncomfortable,”[82] and “dreaded,”[61] which was later on accepted as “necessary,” [82] and “routine.”[61]

Survival imperative–Improving their chance of survival through early detection motivated men to undergo prostate cancer screening.[20, 21, 28, 36, 42, 43, 60, 71, 74, 77, 85, 91, 92] Early detection was perceived as imperative to prevent severe morbidity or mortality, so they could continue to live a “normal life.”[21] They believed that cancers detected early had a “higher chance”[20] of cure.

Peace of mindThe possibility of prostate cancer was often “constantly nagging at the back of their mind”[79] particularly for men with increased risk due to family history of the cancer. Some participants believed they had “nothing to lose”[36] by going ahead with the screening. By doing so, they felt reassured and their “mind was at ease.”[36, 39, 48, 52, 71, 79, 92] Prostate cancer screening provided “peace of mind for family and loved ones too.”[71]

Mental preparationPreparing for the procedure of screening was psychologically confronting and overwhelming for men.[19, 49, 79] The fear of having an invasive procedure required men to be mentally prepared as they were hesitant to commit.[79] [19, 79] After the test, many men felt “anxious”[49] awaiting the results and left with a “great void of uncertainty”[79] as they were terrified to receive a positive result.

Prioritising wellbeingMen valued survival and family: “I want to live as long as I can and be around for my children and grandchildren.”[47] For those who had not experienced severe health problems, they “did not want to run the risk”[77] and instead “wanted to be preventive, instead of regretting”[77] their decision in the future. Some regarded prostate cancer screening as a “win-win situation”[36], and regardless of the outcome, they could “not go wrong.”[36] Some men strived to maintain a sense of control of their body, and were “curious”[54] and wanted to know “what is really going on in my body”[54], and thus were inclined to participate in prostate cancer screening.

Preserving masculinity.

Bodily invasionSome men felt a loss of personal dignity after undergoing the invasive procedure of screening.[20, 27, 53, 55, 60, 61, 81, 82, 88, 94, 97, 100] For men who had not previously been screened for prostate cancer they were fearful of the procedure and did not like the idea of a doctor “messing with me there.”[87] For men who had participated they felt the procedure was “violating”[97] and some “felt invaded,”[27, 81, 82, 97] and therefore were unwilling to complete the screening again.[78, 82] Some persevered through the unpleasantness of the procedure by focussing on the necessity–“if I need it I’ll get it done”.[82]

Losing sexualityMen were fearful that consequences of screening may cause sexual dysfunction,[19, 20, 27, 57, 58, 60, 65, 68, 7175, 77, 78, 92, 94, 100] and this was a “major concern.”[19] Being unable to perform sexually would be “devastating.”[27] Prostate cancer and subsequent prostatectomy was seen as “taking the manhood away”[71] and thus men were reluctant to undergo screening. They wanted to avoid diagnosis of prostate cancer as they did “not want to end up impotent,”[77] which some had observed in other men who had been treated for prostate cancer.

Threatening manhoodBeing diagnosed with prostate cancer was perceived to potentially jeopardise a man’s manhood or masculinity.[19, 39, 41, 42, 51, 53, 55, 57, 60, 6366, 69, 70, 72, 74, 75, 78, 82, 84, 88, 89, 94, 96, 97] Their “macho man”[53] image would be compromised, as “being unhealthy is a sign of being unmanly.”[66] Some men were uneasy and reluctant to be screened as the DRE was perceived to have “homosexual implications.”[19, 51, 69, 74, 89] Some also feared being diagnosed with prostate cancer as they would have to relinquish their role as “the rock”[66] of their family.

Medical avoidanceSome participants were generally averse to interacting with the medical system, particularly if it was seen as unnecessary given the absence of symptoms or perceptible health problems.[1921, 27, 28, 37, 42, 45, 53, 55, 63, 64, 69, 72, 86, 88, 89, 92] They reasoned that “if it don’t hurt don’t fix it.”[20] Even after been advised by a doctor to undergo further tests or examinations they would “postpone and postpone”[28] as they refused to be seen as vulnerable and were terrified of potentially receiving bad news. Some men believed that it was “not socially acceptable”[69] to go to the doctor like women,[55, 64, 69, 70, 86] which they attributed to their macho mentality[21, 63, 72]–that they were “tough”[72] and “infallible.”[21]

Avoiding the unknown and uncertainties.

Taboo of cancer-related deathFears of being potentially diagnosed with prostate cancer and dying caused men to ignore the matter.[19, 20, 28, 36, 37, 39, 41, 42, 54, 56, 62, 63, 7779, 88, 92, 96, 99, 100] In one study, African American men felt that “anything that a Black man thinks is gonna kill him, he ain’t gonna want to talk about”.[41] Cancer was considered to be “a death sentence,”[28] and men expressed that they would “rather not know”.[27] For men who had previous or ongoing health problems, they were particularly concerned that another diagnosis i.e. of prostate cancer would increase the burden of living with the disease to beyond what they could cope with.

Lacking tangible causeThe absence of signs and symptoms made it difficult for men to understand the value of screening.[20, 36, 43, 50, 58, 62, 64, 69, 74, 8486, 89, 98] Some felt they were healthy and were convinced that “if it’s not affecting me, why bother with it?”[86] as there was “nothing wrong…no pain or disease.”[50]

Physiological and symptomatic obscurity–Although participants indicated their awareness of prostate cancer, some did not know “what the gland’s there for, we don’t know what it does, so we don’t know what to do.”[44] One participant highlighted that he was “pretty ignorant“[46] as he “didn’t even know women didn’t get it.”[46] Some younger men felt there was no need to spend time and money for screening as prostate cancer was an “old man”[50] cancer. Further, participants had lack of awareness of the symptoms of prostate cancer.

Ambiguity of the procedureSome men described having a vague understanding of the procedures of prostate cancer screening, which caused them to feel concerned and anxious about undergoing screening.[36, 42, 54, 65, 88, 91] Screening was at times acted upon because they received instruction by their doctor, although they had little knowledge regarding the PSA testing.[91] Due to lack of knowledge and awareness, some men stated there was “too much confusion” and assumed that all prostate cancer screening was “invasive”[36] and “painful.”[88] However, some became aware that a blood test was available, and were relieved that they would not have to undergo a DRE.[36]

Confusing controversiesThe controversies regarding the accuracy of prostate cancer screening caused some men to feel confused and uncertain.[21, 36, 38, 46, 52, 62, 65, 67, 69, 83, 92, 95] They questioned “what’s the point of getting a test if it might not be reliable?”[62] For others, they found the procedure “not that reassuring,”[46] as there was still a chance they could have prostate cancer. Thus, decision making was complex as they had to “evaluate the pros and cons”[38] in the context of such uncertainties. Some men also disclosed that the potential risks involved in prostate cancer screening were not addressed by doctors, despite highlighting the benefits of the procedure. [93]

Prohibitive costs.

The cost of prostate cancer screening created difficulty for men seeking participation[19, 20, 27, 40, 54, 60, 64, 80, 89, 90] as many were not “able to afford the doctors.”[40] However, concerns regarding costs were only identified among African American and African-Caribbean participants in the United States. In 14 studies involving African American men, men disclosed that they could not afford health insurance and therefore were unable to be screened for prostate cancer despite their increased risk.[19, 20, 27, 39, 40, 54, 62, 64, 71, 73, 76, 80, 87, 89] African-Caribbean men also articulated that “health insurance is probably the biggest impediment”[60] for men to regularly partake in screening.


Our findings demonstrate that men’s expectations and values regarding prostate cancer screening reflects a complex decisional matrix. Active recommendation to screen from health care providers, persuasion from their close social networks, and exposure to personal experience of cancer supported men’s acceptance and willingness to undergo prostate cancer screening. Further, men believed that early detection could improve chances of survival, which was also a strong motivator to participate in screening. However, some men refused or delayed prostate cancer screening as risks such as erectile dysfunction were regarded as a threat to their masculinity and bodily dignity, Also, men were reluctant to contemplate mortality as it was too confronting (or perceived as irrelevant by younger men), or were anxious about the unknowns and uncertainties of the procedure and the potential distress if screened positive for prostate cancer.

Our review also highlights differences in men’s perspectives of prostate cancer screening by age, ethnicity and family history of prostate cancer. Some younger men felt they had less knowledge about the risk of prostate cancer, and assumed that screening was not relevant at their age as prostate cancer was thought to be more prevalent in older men. Although African American men have an increased risk of prostate cancer, they felt their knowledge of the disease was limited compared to other populations, and identified cost as a major barrier to screening. Many men who had a family history of prostate cancer were acutely aware of the consequences on health and quality life, and were thus motivated to participate in screening. However, we did not identify any clear differences by country.

The decision making process for prostate cancer screening align with the domains of the Integrated Behaviour Model, which has been commonly used to explain decision making in cancer screening.[102, 103] The model theorises that intentions (founded by attitudes, subjective norms and perceived self-efficacy) are the predominant determinants of enacting behaviour; while ability, environmental constraints and habit directly enable or constrain the resulting action.[104, 105] Thus, our findings demonstrate that men’s decision making for prostate cancer screening is influenced by knowledge obtained through support networks and other means, the personal impact of knowing someone who has suffered from cancer, and their motivation to maintain their wellbeing. However, the only environmental constraint identified in the review was the out-of-pocket costs of screening, which varied by jurisdiction.

Our findings are consistent with similar studies for other cancers. Receiving a direct recommendation from a health care provider to undergo screening has also been found to prompt and reinforce motivation for participation in bowel,[106, 107] breast,[108110] and cervical cancer screening.[111, 112] Other facilitators of screening also include early detection and prevention of cancer,[109, 112, 113] peace of mind,[114116] and being in control of own health.[113, 114] Studies have also shown that patients are conscious of their own lack of awareness about the risk and harms of screening, which contributes to uncertainties in decision making.[117119] In terms of barriers, concerns about invasion of privacy in screening have also been documented in the context of cervical cancer.[120] In prostate cancer screening, sexual impotence was identified as a major concern in our study. However in contrast, findings from a discrete choice experiment suggests that the risk of erectile dysfunction did not significantly influence men’s preferences for screening, and men were more willing to accept this potential harm to avoid prostate cancer related death.[121]

Our review involved a systematic and comprehensive literature search, and we synthesized 68 qualitative studies, with 3,029 participants from nine countries to develop a new analytical framework reflecting the complexities in decision-making about prostate cancer screening among men. We also conducted an independent assessment of the transparency of study reporting. However, there are some potential limitations. Although one author coded the studies, the preliminary findings and coding were discussed with multiple investigators who had read the papers, to enhance the analytical framework and to ensure that the full spectrum of perspectives reported in the primary studies were included in the final analysis. We excluded non-English articles to minimise cultural and linguistic misinterpretation. Also, we were unable to delineate differences between types of screening modality as these were not specified in most studies, and whether perspectives varied according to whether men had actually experienced screening.

The lack of understanding about the process and risk of screening, and the potential threat to masculinity as a consequence of further interventions if screened positive, compound the complexities of men’s decision-making about prostate cancer screening. This suggests the need for accessible and comprehensive information about the screening procedure, the potential benefits and harms of screening; particularly as shared decision making about prostate cancer screening is still not being widely implemented in primary healthcare settings.[122] Current guidelines for prostate cancer screening recommend against prostate cancer screening or suggest a shared decision making approach that address the benefits and harms for specific ages or high risk groups.[11, 1416] They also suggest consideration of men’s preferences and values; however they do not explicitly mention the values that are important to men which were disclosed in our review, and includes invasion of privacy, masculinity and impotence.

Decision aids may be beneficial for presenting population based evidence on benefits and harms of screening, but implementation can be challenging. Randomised controlled trials have shown that decision aids can improve informed decisions, communication between patients and health can providers, and therefore facilitate informed decision making.[123125] Further, trials specific to prostate cancer screening, have found decision aids improve knowledge of PSA testing and reduced men’s desire to undergo screening.[126] However, at present, information on the harms of overdiagnosis and overtreatment is rarely presented.[127] Further, decision aids have not been widely implemented,[128] due to barriers including insufficient practitioner time, unawareness of and access to decision aids, and possibly lack of skills to utilise with patients in a clinical environment.[129132]

Our findings demonstrate that participation in prostate cancer screening is informed by an individual’s subjective norms. Although routine screening for prostate cancer screening is not recommended, many men participate and remain enthusiastic about screening, as they believe that early detection prevents cancer.[133] In light of the potential harms of screening, addressing individual and community perceptions of prostate cancer screening through communication and health messages is important to normalise the decision to forgo prostate cancer screening.[134]

Therefore we suggest further work to gain understanding about what men understand about overdiagnosis as this does not appear to be explicitly addressed in existing studies. This could include eliciting their attitudes, reactions and choices made when provided with such information, and the harms and risks men prioritise, and how these potentially impact the decision making process, as has been done in the context of breast cancer.[135] As in other previous work in breast cancer screening,[134] assessing the impact of recent policy changes to prostate cancer screening uptake and understanding awareness of the guidelines changes, the controversy, and what formulates decision making is imperative to develop interventions that can improve the decision making process regarding prostate cancer screening.

As clinician recommendation is an important contributor to prostate cancer screening decisions, an understanding of how pre-screening discussions are conducted in clinical practice is important. Future studies are needed to promote shared decision making about prostate cancer screening. Further, research regarding shared decision making should focus not only on shared decision making as an outcome but also through understanding the processes of formulating a decision, delivering of information of the procedure and associated benefits and harms, and patient’s emotional experience and attitudes towards the decision making process. This will facilitate identification of best practices to disseminate shared decision making interventions.

Prostate cancer screening is sourced and accepted by men in order to prevent cancer-related morbidity and mortality and gain reassurance about their health. Their willingness to screen is informed by their primary care providers and support networks. However fears regarding their masculinity and invasiveness of the procedure, and hesitation relating to the ambiguities of the effectiveness, necessity and costs of screening, also contribute to their decision-making. Addressing the concerns and priorities of men regarding prostate cancer screening may empower men to make more informed decisions that reflect their personal priorities, preferences and values, and improve patient satisfaction and outcomes.

Transparency declaration: LJJ affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.


  1. 1. Cancer Research UK. Prostate cancer mortality statistics 2015. Available from:, Accessed August 2016.
  2. 2. Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer. Sydney: Cancer Council Australia.
  3. 3. Cancer Research UK. Prostate cancer statistics. Available from:, Accessed August 2016.
  4. 4. Cancer Research UK. Prostate cancer incidence statistics. Available from:, Accessed August 2016.
  5. 5. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
  6. 6. Australian Institute of Health and Welfare (AIHW). Australian cancer incidence and mortality (ACIM) books: prostate cancer. Canberra: AIHW2016. Available from:
  7. 7. Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ. 2013;346:f325. Epub 2013/01/31. pmid:23360718; PubMed Central PMCID: PMCPmc3938276.
  8. 8. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32. Epub 2012/01/10. pmid:22228146; PubMed Central PMCID: PMCPmc3260132.
  9. 9. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35. pmid:25108889
  10. 10. Eggener SE, Cifu AS, Nabhan C. Prostate cancer screening. JAMA. 2015;314(8):825–6. pmid:26305653
  11. 11. Moyer VA. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;157(2):120–34. pmid:22801674
  12. 12. Bell N, Gorber SC, Shane A, Joffres M, Singh H, Dickinson J, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014;186(16):1225–34. pmid:25349003
  13. 13. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med. 2008;149(3):192–9. pmid:18678846
  14. 14. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419–26. pmid:23659877
  15. 15. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology. 2014;65(1):124–37. Epub 2013/11/12. pmid:24207135.
  16. 16. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158(10):761–9. Epub 2013/04/10. pmid:23567643.
  17. 17. Ilic D, O’Connor D, Green S, Wilt T. Screening for prostate cancer: A Cochrane systematic review. Cancer Causes & Control. 2007;18(3):279–85. pmid:17206534
  18. 18. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European urology. 2011;59(1):61–71. Epub 2010/11/09. pmid:21056534.
  19. 19. Allen JD, Kennedy M, Wilson-Glover A, Gilligan TD. African-American men's perceptions about prostate cancer: implications for designing educational interventions. Social science & medicine. 2007;64(11):2189–200. pmid:17399877.
  20. 20. Forrester-Anderson IT. Prostate cancer screening perceptions, knowledge and behaviors among African American men: focus group findings. Journal of health care for the poor and underserved. 2005;16(4 Suppl A):22–30. pmid:16327094.
  21. 21. McFall SL, Hamm RM, Volk RJ. Exploring beliefs about prostate cancer and early detection in men and women of three ethnic groups. Patient education and counseling. 2006;61(1):109–16. pmid:16256292.
  22. 22. Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: Evidence of an increased need for shared decision making. Cancer. 2014;120(10):1491–8. pmid:24523016
  23. 23. Hoffman RM, Lewis CL, Pignone MP, Couper MP, Barry MJ, Elmore JG, et al. Decision-Making Processes for Breast, Colorectal, and Prostate Cancer Screening: The DECISIONS Survey. Med Decis Making. 2010;30(5 suppl):53S–64S. pmid:20881154
  24. 24. So WK, Choi KC, Tang WP, Lee PC, Shiu AT, Ho SS, et al. Uptake of prostate cancer screening and associated factors among Chinese men aged 50 or more: a population-based survey. Cancer biology & medicine. 2014;11(1):56–63. Epub 2014/04/17. pmid:24738039; PubMed Central PMCID: PMCPmc3969801.
  25. 25. Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. American journal of public health. 2000;90(10):1595–600. Epub 2000/10/13. pmid:11029994; PubMed Central PMCID: PMCPmc1446381.
  26. 26. Shelton P, Weinrich S, Reynolds WA Jr. Barriers to prostate cancer screening in African American men. Journal of National Black Nurses' Association: JNBNA. 1999;10(2):14–28. Epub 2000/03/25. pmid:10732593.
  27. 27. Blocker DE, Romocki LS, Thomas KB, Jones BL, Jackson EJ, Reid L, et al. Knowledge, beliefs and barriers associated with prostate cancer prevention and screening behaviors among African-American men. J Natl Med Assoc. 2006;98(8):1286–95. pmid:16916126; PubMed Central PMCID: PMCPMC2569547.
  28. 28. Conde FA, Landier W, Ishida D, Bell R, Cuaresma CF, Misola J. Barriers and facilitators of prostate cancer screening among Filipino men in Hawaii. Oncology nursing forum. 2011;38(2):227–33. pmid:21356660; PubMed Central PMCID: PMCNIHMS457529 PMC3662804.
  29. 29. Consedine NS, Morgenstern AH, Kudadjie-Gyamfi E, Magai C, Neugut AI. Prostate cancer screening behavior in men from seven ethnic groups: the fear factor. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(2):228–37. Epub 2006/02/24. pmid:16492909.
  30. 30. Ghodsbin F, Zare M, Jahanbin I, Ariafar A, Keshavarzi S. A Survey of the Knowledge and Beliefs of Retired Men about Prostate Cancer Screening Based on Health Belief Model. International journal of community based nursing and midwifery. 2014;2(4):279–85. Epub 2014/10/29. pmid:25349871; PubMed Central PMCID: PMCPmc4201208.
  31. 31. Lee DJ, Consedine NS, Spencer BA. Barriers and facilitators to digital rectal examination screening among African-American and African-Caribbean men. Urology. 2011;77(4):891–8. Epub 2011/04/12. pmid:21477716; PubMed Central PMCID: PMCPmc3092791.
  32. 32. Consedine NS, Adjei BA, Ramirez PM, McKiernan JM. An object lesson: source determines the relations that trait anxiety, prostate cancer worry, and screening fear hold with prostate screening frequency. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17(7):1631–9. Epub 2008/07/17. pmid:18628414.
  33. 33. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC medical research methodology. 2012;12:181. Epub 2012/11/29. pmid:23185978; PubMed Central PMCID: PMCPmc3552766.
  34. 34. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International journal for quality in health care: journal of the International Society for Quality in Health Care / ISQua. 2007;19(6):349–57. Epub 2007/09/18. pmid:17872937.
  35. 35. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC medical research methodology. 2008;8:45. Epub 2008/07/12. pmid:18616818; PubMed Central PMCID: PMCPmc2478656.
  36. 36. Avery KNL, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial. European urology. 2008;53(6):1186–93. pmid:17709169.
  37. 37. Drummond MJN, Laws TA, Poljak-Fligic J. Knowledge of and attitudes towards prostate cancer among Italo-Australian men. Aust J Prim Health. 2001;7(3):9–16. pmid:2002054484.
  38. 38. Dube CE, Fuller BK, Rosen RK, Fagan M, O'Donnell J. Men's experiences of physical exams and cancer screening tests: a qualitative study. Preventive medicine. 2005;40(6):628–35. pmid:15850858.
  39. 39. Ford ME, Vernon SW, Havstad SL, Thomas SA, Davis SD. Factors influencing behavioral intention regarding prostate cancer screening among older African-American men. J Natl Med Assoc. 2006;98(4):505–14. pmid:16623062; PubMed Central PMCID: PMCPMC2569259.
  40. 40. Friedman DB, Corwin SJ, Dominick GM, Rose ID. African American men's understanding and perceptions about prostate cancer: why multiple dimensions of health literacy are important in cancer communication. Journal of community health. 2009;34(5):449–60. pmid:19517223.
  41. 41. Friedman DB, Thomas TL, Owens OL, Hebert JR. It takes two to talk about prostate cancer: a qualitative assessment of African American men's and women's cancer communication practices and recommendations. American journal of men's health. 2012;6(6):472–84. pmid:22806569; PubMed Central PMCID: PMCNIHMS388306 PMC3463645.
  42. 42. Fyffe DC, Hudson SV, Fagan JK, Brown DR. Knowledge and barriers related to prostate and colorectal cancer prevention in underserved black men. J Natl Med Assoc. 2008;100(10):1161–7. pmid:18942277.
  43. 43. Hannover W, Kopke D, Hannich HJ. Perceived Barriers to Prostate Cancer Screenings Among Middle-Aged Men in North-Eastern Germany. Public health nursing. 2010;27(6):504–12. pmid:21087303.
  44. 44. Horwood JP, Avery KN, Metcalfe C, Donovan JL, Hamdy FC, Neal DE, et al. Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. BMC Cancer. 2014;14:812. pmid:25374269; PubMed Central PMCID: PMCPMC4232627.
  45. 45. Ilic D. Educating men about prostate cancer in the workplace. American journal of men's health. 2013a;7(4):285–94. pmid:23154199.
  46. 46. Ilic D, Murphy K, Green S. Perspectives on knowledge, information seeking, and decision-making behavior about prostate cancer among Australian men. J Mens Health. 2013b;10(2):54–9. pmid:2014073517.
  47. 47. Jones RA, Steeves R, Williams I. Family and friend interactions among African-American men deciding whether or not to have a prostate cancer screening. Urol Nurs. 2010;30(3):189–93, 66. pmid:20648856; PubMed Central PMCID: PMCNIHMS453709 PMC3616189.
  48. 48. Matthew AG, Paradiso C, Currie KL, Finelli A, Hartman M-E, Trachtenberg L, et al. Examining risk perception among men with a family history of prostate cancer. Patient education and counseling. 2011;85(2):251–7. pmid:21310580
  49. 49. McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR. False-positive cancer screens and health-related quality of life. Cancer Nurs. 2004;27(5):347–52. pmid:15525861.
  50. 50. Nakandi H, Kirabo M, Semugabo C, Kittengo A, Kitayimbwa P, Kalungi S, et al. Knowledge, attitudes and practices of Ugandan men regarding prostate cancer. African journal of urology: the official journal of the Pan African Urological Surgeons' Association. 2013;19(4):165–70. pmid:2013734965.
  51. 51. Ocho ON, Green J. Perception of prostate screening services among men in Trinidad and Tobago. Sex Res Soc Policy. 2013;10(3):186–92. PubMed PMID: 2013-11313-001.
  52. 52. Rai T, Clements A, Bukach C, Shine B, Austoker J, Watson E. What influences men's decision to have a prostate-specific antigen test? A qualitative study. Family practice. 2007;24(4):365–71. pmid:17644829.
  53. 53. Rivera-Ramos ZA, Buki LP. I will no longer be a man! Manliness and prostate cancer screenings among Latino men. Psych Men Masc. 2011;12(1):13–25. PubMed PMID: 2011-00514-002.
  54. 54. Taylor MC. The impact of community health centers on prostate cancer screening behaviors of African American males: A mixed methods study [Dissertation Empirical Study; Interview; Qualitative Study; Quantitative Study]2013.
  55. 55. Webb CR, Kronheim L, Williams JE Jr, Hartman TJ. An evaluation of the knowledge, attitudes, and beliefs of African-American men and their female significant others regarding prostate cancer screening. Ethn Dis. 2006;16(1):234–8. pmid:16599376.
  56. 56. Zimmerman SM. Factors influencing Hispanic participation in prostate cancer screening. Oncology nursing forum. 1997;24(3):499–504. pmid:9127362.
  57. 57. Engelen A, Vanderhaegen J, Van Poppel H, Van Audenhove C. The use of decision aids on early detection of prostate cancer: Views of men and general practitioners. Health Expect. 2016;(Pagination):No Pagination Specified. PubMed PMID: 2016-09286-001.
  58. 58. Gittens HC. Prostate cancer screening of heterosexual Caribbean American and African American men and their partners. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2016;76(10-B(E)):No Pagination Specified. PubMed PMID: 2016-16234-047.
  59. 59. Sutkowi-Hemstreet A, Vu M, Harris R, Brewer NT, Dolor RJ, Sheridan SL. Adult Patients' Perspectives on the Benefits and Harms of Overused Screening Tests: a Qualitative Study. J Gen Intern Med. 2015;30(11):1618–26. pmid:25869017.
  60. 60. Taitt HE. Prostate cancer and afro-caribbean men: Experiences, perceptions, and beliefs. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2016;76(7-B(E)):No Pagination Specified. PubMed PMID: 2016-99020-412.
  61. 61. Dale W. Evaluating focus group data: barriers to screening for prostate cancer patients. Cancer Treat Res. 1998;97:115–28. pmid:9711413.
  62. 62. Ferrante J, Shaw E, Scott J. Factors Influencing Men's Decisions Regarding Prostate Cancer Screening: A Qualitative Study. Journal of community health. 2011;36(5):839–44. pmid:21336996. Language: English. Entry Date: 20111007. Revision Date: 20121012. Publication Type: journal article.
  63. 63. George A, Fleming P. Factors affecting men's help-seeking in the early detection of prostate cancer: Implications for health promotion. J Mens Health. 2004;1(4):345–52. pmid:2005161341.
  64. 64. Griffith DM, Mason MA, Rodela M, Matthews DD, Tran A, Royster M, et al. A structural approach to examining prostate cancer risk for rural Southern African American Men. Journal of health care for the poor and underserved. 2007;18(4 SUPPL.):73–101. pmid:18065853.
  65. 65. Gwede CK, Davis SN, Wilson S, Patel M, Vadaparampil ST, Meade CD, et al. Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. Am J Health Promot. 2015;29(6):393–401. pmid:24968183. Language: English. Entry Date: In Process. Revision Date: 20150731. Publication Type: journal article. Journal Subset: Blind Peer Reviewed.
  66. 66. Harvey IS, Alston RJ. Understanding preventive behaviors among mid-Western African-American men: A pilot qualitative study of prostate screening. J Mens Health. 2011;8(2):140–51. pmid:21743817.
  67. 67. McFall SL, Hamm RM. Interpretation of prostate cancer screening events and outcomes: A focus group study. Patient education and counseling. 2003;49(3):207–18. pmid:12642192.
  68. 68. Meade CD, Calvo A, Rivera MA, Baer RD. Focus groups in the design of prostate cancer screening information for Hispanic farmworkers and African American men. Oncology nursing forum. 2003;30(6):967–75. pmid:14603354.
  69. 69. Nash C, Hall C. Prostate cancer in Arkansas. J Ark Med Soc. 2002;98(10):331–8. pmid:11951790.
  70. 70. Ng P, Schoenfeld ER, Hennis A, Wu SY, Leske MC, Nemesure B. Factors influencing prostate cancer healthcare practices in Barbados, West Indies. Journal of immigrant and minority health / Center for Minority Public Health. 2013;15(3):653–60. pmid:22669639.
  71. 71. Odedina FT, Scrivens J, Emanuel A, LaRose-Pierre M, Brown J, Nash R. A focus group study of factors influencing African-American men's prostate cancer screening behavior. J Natl Med Assoc. 2004;96(6):780–8. pmid:15233488; PubMed Central PMCID: PMCPMC2568374.
  72. 72. Pinnock C, O'Brien B, Marshall VR. Older men's concerns about their urological health: a qualitative study. Aust N Z J Public Health. 1998;22(3 Suppl):368–73. pmid:9629824.
  73. 73. Richardson JT, Webster JD, Fields NJ. Uncovering myths and transforming realities among low-SES African-American men: implications for reducing prostate cancer disparities. J Natl Med Assoc. 2004;96(10):1295–302. pmid:15540880; PubMed Central PMCID: PMCPMC2568560.
  74. 74. Sanchez MA, Bowen DJ, Hart A Jr, Spigner C. Factors influencing prostate cancer screening decisions among African American men. Ethn Dis. 2007;17(2):374–80. pmid:17682373.
  75. 75. Woods VD, Montgomery SB, Belliard JC, Ramirez-Johnson J, Wilson CM. Culture, black men, and prostate cancer: what is reality? Cancer Control. 2004;11(6):388–96. pmid:15625526.
  76. 76. Wray RJ, McClure S, Vijaykumar S, Smith C, Ivy A, Jupka K, et al. Changing the conversation about prostate cancer among African Americans: results of formative research. Ethn Dis. 2009;14(1):27–43. pmid:19152157.
  77. 77. Farrell MH, Murphy MA, Schneider CE. How underlying patient beliefs can affect physician-patient communication about prostate-specific antigen testing. Eff Clin Pract. 2002;5(3):120–9. pmid:12088291.
  78. 78. Hill KS. An exploratory case study of African American men on the decision making of prostate cancer screening [Dissertation Clinical Case Study; Empirical Study; Qualitative Study]2013.
  79. 79. Bancroft EK, Castro E, Bancroft GA, Ardern-Jones A, Moynihan C, Page E, et al. The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. Psycho-oncology. 2015;24(11):1492–9. PubMed PMID: 2015-16805-001. pmid:25872100
  80. 80. Bryan CJ, Wetmore-Arkader L, Calvano T, Deatrick JA, Giri VN, Watkins Bruner D. Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk. J Natl Med Assoc. 2008;100(6):674–82. PubMed PMID: 2008-08701-002. pmid:18595569
  81. 81. Clarke-Tasker VA, Wade R. What we thought we knew: African American males' perceptions of prostate cancer and screening methods. Abnf J. 2002;13(3):56–60. pmid:12108141.
  82. 82. Edwards QT. Differentiation of health behavior patterns related to prostate cancer screening among African-American men in military settings: Catholic University of America; 2000.
  83. 83. Evans R, Edwards AGK, Elwyn G, Watson E, Grol R, Brett J, et al. 'It's a maybe test': Men's experiences of prostate specific antigen testing in primary care. Br J Gen Pract. 2007;57(537):303–10. pmid:17394734.
  84. 84. Hicks EM, Litwin MS, Maliski SL. Latino men and familial risk communication about prostate cancer. Oncology nursing forum. 2014;41(5):509–16. pmid:25158656; PubMed Central PMCID: PMCNIHMS647290 PMC4266463.
  85. 85. Ilic D, Risbridger GP, Green S. The informed man: Attitudes and information needs on prostate cancer screening. J Mens Health. 2005;2(4):414–20. pmid:2005560820.
  86. 86. Madjar I, Denham J, Rashid P. Do women have a role in early detection of prostate cancer?—Lessons from a qualitative study. Aust Fam Physician. 2007;36(5):375–7. pmid:17492077.
  87. 87. Marks JP, Reed W, Colby K, Ibrahim SA. A culturally competent approach to cancer news and education in an inner city community: Focus group findings. Journal of health communication. 2004;9(2):143–57. pmid:15204825.
  88. 88. Oliver JS. Attitudes and beliefs about prostate cancer and screening among rural African American men. J Cult Divers. 2007;14(2):74–80. pmid:19175247.
  89. 89. Robinson SB, Ashley M, Haynes MA. Attitudes of African Americans regarding screening for prostate cancer. J Natl Med Assoc. 1996;88(4):241–6. pmid:8648660; PubMed Central PMCID: PMCPMC2608049.
  90. 90. Ross L, Kohler CL, Grimley DM, Green BL, Anderson-Lewis C. Toward a model of prostate cancer information seeking: identifying salient behavioral and normative beliefs among African American men. Health education & behavior: the official publication of the Society for Public Health Education. 2007;34(3):422–40. pmid:17142243.
  91. 91. Enaworu OU, Khutan R. Factors influencing Nigerian men's decision to undergo prostate specific antigen testing. African Health Sciences. 2016;16(2):524–32. pmid:27605968.
  92. 92. Hunter JC, Vines AI, Carlisle V. African Americans’ Perceptions of Prostate-Specific Antigen Prostate Cancer Screening. Health education & behavior: the official publication of the Society for Public Health Education. 2015;42(4):539–44. pmid:109824818. Language: English. Entry Date: 20150825. Revision Date: 20150923. Publication Type: Journal Article.
  93. 93. Owens OL, Friedman DB, Brandt HM, Bernhardt JM, Hebert JR. Digital solutions for informed decision making: An academic-community partnership for the development of a prostate cancer decision aid for African American men. American journal of men's health. 2016;10(3):207–19. PubMed PMID: 2016-18081-005. pmid:25563381
  94. 94. Seymour-Smith S, Brown D, Cosma G, Shopland N, Battersby S, Burton A. "Our people has got to come to terms with that": Changing perceptions of the digital rectal examination as a barrier to prostate cancer diagnosis in African-Caribbean men. Psycho-oncology. 2016. pmid:612176024.
  95. 95. Taylor KL, Turner RO, Davis JL 3rd, Johnson L, Schwartz MD, Kerner J, et al. Improving knowledge of the prostate cancer screening dilemma among African American men: an academic-community partnership in Washington, DC. Public Health Rep. 2001;116(6):590–8. pmid:12196619; PubMed Central PMCID: PMCPMC1497383.
  96. 96. Winterich JA, Grzywacz JG, Quandt SA, Clark PE, Miller DP, Acuna J, et al. Men's knowledge and beliefs about prostate cancer: education, race, and screening status. Ethn Dis. 2009a;19(2):199–203. pmid:19537233; PubMed Central PMCID: PMCNIHMS89549 PMC2699598.
  97. 97. Winterich JA, Quandt SA, Grzywacz JG, Clark PE, Miller DP, Acuna J, et al. Masculinity and the body: how African American and White men experience cancer screening exams involving the rectum. American journal of men's health. 2009b;3(4):300–9. pmid:19477742.
  98. 98. Woods VD, Montgomery SB, Herring RP. Recruiting Black/African American men for research on prostate cancer prevention. Cancer. 2004;100(5):1017–25. pmid:14983498.
  99. 99. Woods VD, Montgomery SB, Herring RP. Recruiting Black/African American men for research on prostate cancer prevention. Cancer. 2004b;100(5):1017–25. pmid:14983498.
  100. 100. Woods VD, Montgomery SB, Belliard JC, Ramirez-Johnson J, Wilson CM. Culture, black men, and prostate cancer: what is reality? Cancer Control. 2004a;11(6):388–96. pmid:15625526.
  101. 101. George A, Fleming P. Factors affecting men's help-seeking in the early detection of prostate cancer: Implications for health promotion. J Mens Health 2004;1(4):345–52. pmid:2005161341.
  102. 102. Jimbo M, Rana GK, Hawley S, Holmes-Rovner M, Kelly-Blake K, Nease DE, et al. What is lacking in current decision aids on cancer screening? CA Cancer J Clin. 2013;63(3):193–214. PubMed PMID: PMC3644368. pmid:23504675
  103. 103. Frosch DL, Legare F, Fishbein M, Elwyn G. Adjuncts or adversaries to shared decision-making? Applying the Integrative Model of behavior to the role and design of decision support interventions in healthcare interactions. Implementation science: IS. 2009;4:73. Epub 2009/11/17. pmid:19909547; PubMed Central PMCID: PMCPmc2781788.
  104. 104. Fishbein M. The role of theory in HIV prevention. AIDS care. 2000;12(3):273–8. Epub 2000/08/06. pmid:10928203.
  105. 105. Fishbein M, Yzer MC. Using Theory to Design Effective Health Behavior Interventions. Commun Theory. 2003;13(2):164–83.
  106. 106. Javanparast S, Ward PR, Carter SM, Wilson CJ. Barriers to and facilitators of colorectal cancer screening in different population subgroups in Adelaide, South Australia. Med J Aust. 2012;196(8):521–3. pmid:22571311
  107. 107. Kimura A, Sin MK, Spigner C, Tran A, Tu SP. Barriers and facilitators to colorectal cancer screening in Vietnamese Americans: a qualitative analysis. Journal of cancer education: the official journal of the American Association for Cancer Education. 2014;29(4):728–34. Epub 2014/04/24. pmid:24756545; PubMed Central PMCID: PMCPmc4334440.
  108. 108. Kissal A, Beser A. Knowledge, facilitators and perceived barriers for early detection of breast cancer among elderly Turkish women. Asian Pacific journal of cancer prevention: APJCP. 2011;12(4):975–84. Epub 2011/07/28. pmid:21790237.
  109. 109. Ishida DN, Toomata-Mayer TF, Braginsky NS. Beliefs and attitudes of Samoan women toward early detection of breast cancer and mammography utilization. Cancer. 2001;91(1 Suppl):262–6. Epub 2001/01/10. pmid:11148591.
  110. 110. Wu T-Y, Bancroft J, editors. Filipino American Women's Perceptions and Experiences With Breast Cancer Screening. Oncology nursing forum; 2006.
  111. 111. Kwok C, White K, Roydhouse JK. Chinese-Australian women's knowledge, facilitators and barriers related to cervical cancer screening: a qualitative study. Journal of immigrant and minority health / Center for Minority Public Health. 2011;13(6):1076–83. Epub 2011/06/15. pmid:21667256.
  112. 112. Brown DR, Wilson RM, Boothe MA, Harris CE. Cervical cancer screening among ethnically diverse black women: knowledge, attitudes, beliefs, and practices. J Natl Med Assoc. 2011;103(8):719–28. Epub 2011/11/04. pmid:22046849.
  113. 113. Byrd TL, Chavez R, Wilson KM. Barriers and facilitators of cervical cancer screening among Hispanic women. Ethn Dis. 2007;17(1):129–34. Epub 2007/02/06. pmid:17274222.
  114. 114. Agurto I, Bishop A, Sanchez G, Betancourt Z, Robles S. Perceived barriers and benefits to cervical cancer screening in Latin America. Preventive medicine. 2004;39(1):91–8. Epub 2004/06/23. pmid:15207990.
  115. 115. Severino G, Wilson C, Turnbull D, Duncan A, Gregory T. Attitudes towards and beliefs about colorectal cancer and screening using the faecal occult blood test within the Italian-Australian community. Asian Pacific journal of cancer prevention: APJCP. 2009;10(3):387–94. Epub 2009/07/31. pmid:19640179.
  116. 116. Bass SB, Gordon TF, Ruzek SB, Wolak C, Ward S, Paranjape A, et al. Perceptions of colorectal cancer screening in urban African American clinic patients: differences by gender and screening status. Journal of cancer education: the official journal of the American Association for Cancer Education. 2011;26(1):121–8. Epub 2010/05/06. pmid:20443096; PubMed Central PMCID: PMCPmc2974023.
  117. 117. Waller J, Douglas E, Whitaker KL, Wardle J. Women's responses to information about overdiagnosis in the UK breast cancer screening programme: a qualitative study. BMJ open. 2013;3(4). Epub 2013/04/24. pmid:23610383; PubMed Central PMCID: PMCPmc3641428.
  118. 118. Henriksen MJV, Guassora AD, Brodersen J. Preconceptions influence women’s perceptions of information on breast cancer screening: a qualitative study. BMC Research Notes. 2015;8(1):1–9. pmid:26336075
  119. 119. Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013;346. pmid:23344309
  120. 120. Bukirwa A, Mutyoba JN, Mukasa BN, Karamagi Y, Odiit M, Kawuma E, et al. Motivations and barriers to cervical cancer screening among HIV infected women in HIV care: a qualitative study. BMC women's health. 2015;15:82. Epub 2015/10/16. pmid:26458898; PubMed Central PMCID: PMCPmc4603977.
  121. 121. Howard K, Salkeld GP, Patel MI, Mann GJ, Pignone MP. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment. Health Expect. 2015;18(6):3123–35. pmid:25382490
  122. 122. Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, et al. National evidence on the use of shared decision making in prostate-specific antigen screening. Annals of family medicine. 2013;11(4):306–14. Epub 2013/07/10. pmid:23835816; PubMed Central PMCID: PMCPmc3704490.
  123. 123. Salkeld G, Cunich M, Dowie J, Howard K, Patel MI, Mann G, et al. The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening. PloS one. 2016;11(4):e0152999. Epub 2016/04/07. pmid:27050101; PubMed Central PMCID: PMCPmc4822955.
  124. 124. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;(10):Cd001431. Epub 2011/10/07. pmid:21975733.
  125. 125. Williams RM, Davis KM, Luta G, Edmond SN, Dorfman CS, Schwartz MD, et al. Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancer. Patient education and counseling. 2013;91(3):329–36. Epub 2013/01/30. pmid:23357414; PubMed Central PMCID: PMCPmc3727283.
  126. 126. Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P, Kinnersley P, et al. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. Journal of medical Internet research. 2010;12(3):e27. Epub 2010/08/10. pmid:20693148; PubMed Central PMCID: PMCPmc2956331.
  127. 127. Caverly TJ, Hayward RA, Reamer E, Zikmund-Fisher BJ, Connochie D, Heisler M, et al. Presentation of Benefits and Harms in US Cancer Screening and Prevention Guidelines: Systematic Review. J Natl Cancer Inst. 2016;108(6):djv436. Epub 2016/02/27. pmid:26917630.
  128. 128. Ilic D, Jammal W, Chiarelli P, Gardiner RA, Hughes S, Stefanovic D, et al. Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review. Psycho-oncology. 2015. Epub 2015/04/16. pmid:25873433.
  129. 129. Brace C, Schmocker S, Huang H, Victor JC, McLeod RS, Kennedy ED. Physicians' awareness and attitudes toward decision aids for patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(13):2286–92. Epub 2010/04/01. pmid:20354133.
  130. 130. Engelen A, Vanderhaegen J, Van Poppel H, Van Audenhove C. The use of decision aids on early detection of prostate cancer: views of men and general practitioners. Health Expect. 2016. pmid:26890150
  131. 131. O'Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA, Moulton BW, Sepucha KR, et al. Toward the 'tipping point': decision aids and informed patient choice. Health Aff (Millwood). 2007;26(3):716–25. Epub 2007/05/09. pmid:17485749.
  132. 132. Short D, Frischer M, Bashford J. Barriers to the adoption of computerised decision support systems in general practice consultations: a qualitative study of GPs' perspectives. International journal of medical informatics. 2004;73(4):357–62. Epub 2004/05/12. pmid:15135754.
  133. 133. Howard DH, Tangka FK, Guy GP, Ekwueme DU, Lipscomb J. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. Health Aff (Millwood). 2013;32(3):596–602. Epub 2013/03/06. pmid:23459740; PubMed Central PMCID: PMCPmc4818375.
  134. 134. Allen JD, Bluethmann SM, Sheets M, Opdyke KM, Gates-Ferris K, Hurlbert M, et al. Women's responses to changes in U.S. Preventive Task Force's mammography screening guidelines: results of focus groups with ethnically diverse women. BMC public health. 2013;13:1169. Epub 2013/12/18. pmid:24330527; PubMed Central PMCID: PMCPmc3913377.
  135. 135. Hersch J, Barratt A, Jansen J, Irwig L, McGeechan K, Jacklyn G, et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet. 385(9978):1642–52. pmid:25701273